Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate ...
Rivian (RIVN) is rated a Buy, with the R2 launch and proprietary AI/autonomy tech positioning it for long-term EV leadership.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results